Rahway-based Merck & Co. and Isomorphic Labs, a London-based AI-first drug design and development company, announced Nov. 19 a research collaboration that brings together Isomorphic Labs’ AI approach to drug discovery with Merck’s proprietary data resources and discovery experience.
The companies will collaborate to discover therapeutic small molecule candidates against an oncology target of strategic importance. Isomorphic Labs will perform in silico predictions and deliver molecular designs, applying its proprietary drug design engine (IsoDDE) and incorporating select proprietary data sets supplied by Merck for this collaboration. Merck will be responsible for preclinical and clinical development, as well as manufacturing and commercialization of any products derived from the collaboration.